Varian backs Phase III non-small cell lung cancer trial

Varian Medical said today it is supporting a Phase III clinical trial set to compare outcomes of radiosurgery against surgical resection for treating early-stage, high-risk operable non-small cell lung cancer. The randomized “Stablemates Trial” will test the hypothesis that 3-year overall survival in high risk operable patients with Stage I NSCLC is equivalent or greater in patients who undergo stereotactic ablative radiotherapy compared to conventional surgery, the company said.

Mass Device